• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current opinion in hematology >Overcoming drug resistance in chronic myeloid leukemia.
【24h】

Overcoming drug resistance in chronic myeloid leukemia.

机译：在慢性粒细胞白血病中克服耐药性。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE OF REVIEW: Despite the excellent clinical results with imatinib in chronic myeloid leukemia, most patients have minimal residual disease and others will develop resistance and may eventually progress. Thus there is a need for developing approaches to overcome and prevent resistance to imatinib. RECENT FINDINGS: Several new agents have been developed with significant activity in imatinib-resistant chronic myeloid leukemia. A second generation of more potent tyrosine kinase inhibitors, some with dual activity against Abl and Src, have shown very impressive results. Other agents, such as hypomethylating agents, farnesyl transferase inhibitors and homoharringtonine, have also shown preclinical and clinical promise. The use of vaccines as a way of providing an immunomodulatory approach to chronic myeloid leukemia is starting to develop as a major strategy to achieve eradication of the disease. SUMMARY: Multiple effective agents are being developed to overcome resistance to imatinib. The challenge for the future is to incorporate them into effective strategies that can eliminate the disease and cure all patients with chronic myeloid leukemia.
机译：审查目的：尽管伊马替尼在慢性粒细胞白血病中取得了优异的临床结果，但大多数患者的残留病很少，其他患者会产生耐药性并最终可能进展。因此，需要开发克服和预防对伊马替尼耐药性的方法。最近的发现：已经开发了几种对伊马替尼耐药的慢性粒细胞白血病具有显着活性的新药。第二代更有效的酪氨酸激酶抑制剂，其中一些具有针对Abl和Src的双重活性，已显示出令人印象深刻的结果。其他药物，例如次甲基化剂，法呢基转移酶抑制剂和高灵敏素，也已显示出临床前和临床前景。疫苗作为为慢性粒细胞白血病提供免疫调节方法的一种方式，已开始发展成为根除该疾病的主要策略。摘要：正在开发多种有效的药物来克服对伊马替尼的耐药性。未来的挑战是将它们纳入可以消除疾病并治愈所有慢性粒细胞白血病患者的有效策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号